PNEUMOVAX® 23 (PPV23)

CATCH THEM. YOU CAN.

Catch your eligible patients at any time of the year with PNEUMOVAX® 23 to help prevent pneumococcal disease

PNEUMOVAX® 23 (pneumococcal polysaccharide vaccine)
Prescribing Information [External link]

PNEUMOVAX® 23 is recommended for active immunisation against pneumococcal disease in children aged from 2 years, adolescents and adults1

You can reduce the risk of pneumococcal disease

In the UK, people over the age of 65 are at a higher risk of developing pneumococcal disease vs under
65-year-olds.2 Infected patients face longer hospital stays and an increased risk of mortality —
a difficult prospect for their loved ones2,3
Learn more about the impact of pneumococcal disease

70%

of patients hospitalised for CAP*
were over the age of 654

~£6,000

For every CAP hospitalisation
there is a cost of ~£6,0004

69%

of patients aged 65 only and
31% aged 65 and over were
unvaccinated against pneumococcal
disease in 20205

Catch them at any time of year with PNEUMOVAX®23

Most patients only require a single, 0.5 ml dose of PNEUMOVAX®23 by intramuscular or subcutaneous injection to help protect against 23 Pneumococcal serotypes1

PNEUMOVAX®23 can be administered to eligible patients at your clinic at any time of year, without restriction to winter months

Please consult the SmPC for further information before making any prescribing decisions.

By keeping your eligible patients protected, you can help reduce the burden of pneumococcal disease on healthcare systems, including the 40,000 annual hospitalisations6

Find out how administering PNEUMOVAX® 23 at any time of year can help protect patients and hospitals

Find out more

Check who is eligible for PNEUMOVAX® 23 on the National Immunisation Programme

Find out more

Safety Information

Stock ordering and status

Training and Resources

*CAP; community-acquired pneumonia

References

  1. PNEUMOVAX 23 Summary of Product Characteristics.
  2. Grant LR, et al. Expert Rev Vaccines. 2021;20(6):691-705.
  3. NHS. RightCare Community-acquired Pneumonia Toolkit. Available at: https://www.england.nhs.uk/rightcare/wp-content/uploads/sites/40/2022/09/RightCare-Pneumonia-toolkit.pdf. [Date accessed: September 2024].
  4. Campling J, et al. J Med Econ. 2022;25(1):912–918.
  5. Pneumococcal Polysaccharide Vaccine (PPV) coverage report, England, April 2020 to March 2021. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1035189/hpr1921-ppv-vc.pdf. [Accessed: September 2024].
  6. Oxford Vaccine Group. Vaccine Knowledge Project. Pneumococcal disease. Available at: https://vk.ovg.ox.ac.uk/pneumococcal-disease#Key-disease-facts [Accessed: September 2024].

Supporting documentation

PNEUMOVAX® 23 (pneumococcal polysaccharide vaccine)
Prescribing Information

By clicking the link above you will leave the MSD Connect website and be taken to the emc PI portal website

GB-PNX-00556 | Date of Preparation: October 2024